CAMP4 Therapeutics announces Q3 2026 results

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026, CAMP4 Therapeutics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.^{1 1}A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.¹

The information in this Item 2.02 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934², as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press release issued by CAMP4 Therapeutics Corporation on November 5 , 2026.³

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).³

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CAMP4 THERAPEUTICS CORPORATION

By: /s/ Josh Mandel-Brehm⁴

Name: Josh Mandel-Brehm⁴

Title: President and Chief Executive Officer⁴

Date: November 5, 2026

CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights

Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina

Company remains on track to dose first patient by year-end 2026

WATERTOWN, Mass., Nov. 5, 2026 (GLOBE NEWSWIRE) – CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the third quarter ended September 30, 2026, and provided recent corporate highlights.

"The third quarter was one of continued execution for CAMP4. With regulatory clearances now in place in Australia, Argentina, the United Kingdom, and the European Union, we have launched our first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder," said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. "There are no approved disease-modifying treatments for SYNGAP1, and we are committed to rapidly advancing the development of CMP-002 globally in the hopes of offering SYNGAP1 patients and families a potentially transformative solution that could one day dramatically improve their lives."

Recent Corporate Highlights:

• Expanded regulatory approvals for global ASCEND Phase 1/2 clinical trial. Received authorization from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) in September 2026 and received authorization from multiple EU regulators and ethics committees in October 2026 to include UK and EU sites in the global ASCEND Phase 1/2 clinical trial of CMP-002¹¹, building on clearances received in July 2026 from Australia's Therapeutic Goods Administration (TGA) and a local Human Research Ethics Committee (HREC), and from Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT).

• Initiated clinical trial activities across multiple sites. The Company has initiated the ASCEND Phase 1/2 clinical trial of CMP-002 and remains on track to dose the first patient by year-end 2026.¹²

• Hosted Virtual Analyst Day on CMP-002. On September 28, 2026, CAMP4 hosted a Virtual Analyst Day featuring key opinion leader Stéphane Auvin, MD, Ph.D., of Robert Debré University Hospital and Université Paris Cité, as well as patient advocates and members of the CAMP4 leadership team. The program reviewed the unmet need in SYNGAP1-related disorder and the design of the ASCEND clinical trial of CMP-002. The Company also provided an update on its early discovery pipeline, including plans to advance a program targeting SHANK3 regulatory RNA for the potential treatment of Phelan-McDermid syndrome, with a development candidate expected in 2027.

• Completed second closing of private placement. In August 2026, CAMP4 received $50.1 million in gross proceeds from the fully subscribed second closing of its private placement initially announced in September 2025. The second closing was triggered by the regulatory clearance of the CMP-002 clinical trial application in Australia.

Upcoming Investor Conferences

• Guggenheim 3rd Annual Healthcare Innovation Conference, November 9th, Boston, MA.

• Stifel 2026 Healthcare Conference, November 10th, New York, NY.

• Piper Sandler 2026 Healthcare Conference, December 2nd, New York, NY.

Third Quarter 2026 Financial Results

Cash and cash equivalents as of September 30, 2026 were $124.5 million, compared to $109.5 million as of December 31, 2025.⁵ Cash and cash equivalents as of September 30, 2026 reflect the receipt in August 2026 of $50.1 million in gross proceeds from the second closing of the Company's private placement⁶ initially announced in September 2025. The Company believes that its current cash and cash equivalents will be sufficient to fund its planned activities through the end of 2028.⁷

R&D Expenses: Research and development expenses for the quarter ended September 30, 2026 were $11.4 million, compared to $9.9 million for the quarter ended September 30, 2025.⁸ The increase was primarily driven by clinical and preclinical study costs, including activities to support initiation of the Phase 1/2 ASCEND clinical trial of CMP-002.

G&A Expenses: General and administrative expenses were $4.5 million for the quarter ended September 30, 2026, compared to $4.6 million for the quarter ended September 30, 2025.⁹ The decrease was primarily driven by a decrease in professional fees and overhead, partially offset by an increase in stock-based compensation expense.

Net Loss: Net loss for the quarter ended September 30, 2026 was $29.0 million, compared to $15.1 million for the quarter ended September 30, 2025.¹⁰ The increase in net loss was pr